NEW YORK (Reuters Health) – Patients with pulmonary arterial hypertension (PAH) receiving the endothelin A selective antagonist ambrisentan (Letairis, Gilead) no longer need monthly liver function tests. However,…
NEW YORK (Reuters Health) – A program of patient education and planning aimed at treating exacerbations of chronic obstructive pulmonary disease early and reducing rates of hospitalization was…
NEW YORK (Reuters Health) – Nutritional support, mainly in the form of oral nutritional supplements, boosts protein and energy intake, body weight and grip strength in malnourished patients…
NEW YORK (Reuters Health) – In African Americans with moderate-to-severe asthma, treatment for a year with an inhaled combination of budesonide and formoterol is safe and reduces asthma…
NEW YORK (Reuters Health) – Hypoxemia is common in pulmonary hypertension patients during commercial air travel and supplemental in-flight oxygen may be of benefit, researchers report in a…
NEW YORK (Reuters Health) – Despite a guideline in Canada recommending the use of opioids to relieve refractory dyspnea in COPD patients, physicians there are reluctant to do…
NEW YORK (Reuters Health) – In patients with moderate-to-severe chronic obstructive pulmonary disease, twice daily inhalation of either 200 or 400 mcg aclidinium bromide significantly improves FEV1, and…
NEW YORK (Reuters Health) – Results of a meta-analysis show that in preterm infants with respiratory distress syndrome, early use of nasal intermittent positive pressure ventilation (NIPPV) compared…
NEW YORK (Reuters Health) – Goiter should be considered in the differential diagnosis of positional dyspnea, even in patients without obvious thyroid enlargement, according to a new retrospective…
NEW YORK (Reuters Health) – A new analysis of pooled data on omalizumab should help allay concerns that omalizumab (Xolair; Genentech, Novartis) may increase the risk for cancer.…